Compare
Propanc Biopharma, Inc. vs Nomad Power Solutions, Inc. vs PMGC Holdings Inc. vs NRX Pharmaceuticals, Inc.
| Latest fiscal year | Propanc Biopharma, Inc. PPCB | Nomad Power Solutions, Inc. NMAD | PMGC Holdings Inc. ELAB | NRX Pharmaceuticals, Inc. NRXP |
|---|---|---|---|---|
| Year ended | 2026-06-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $590.1K | $1.45M |
| Revenue growth (YoY) | n/a | n/a | n/a | n/a |
| Gross margin | n/a | n/a | 31.4% | 65.1% (computed) |
| Operating margin | n/a | n/a | n/a | n/m |
| Net margin | n/a | n/a | n/m | n/m |
| Net income | -$18.86M | -$6.08M | -$7.75M | -$28.62M |
| EPS (Diluted) | -$17.62 | -$1.26 | n/a | n/a |
| Operating cash flow | -$5.68M | -$3.07M | -$5.93M | -$14.11M |
| Free cash flow | -$5.69M | n/a | -$6.38M | n/a |
| Cash & equivalents | n/a | n/a | n/a | $7.80M |
| Total assets | $12.78M | $12.73M | $12.87M | $12.96M |
| Total liabilities | $3.38M | $1.77M | $5.03M | $28.89M |
| Shareholders' equity | $9.40M | $9.66M | $7.84M | -$15.94M |
| Return on year-end equity | -200.6% | -62.9% | -98.9% | n/a |
| Shares outstanding | 3.31M | 8.79M | 80.7K | 31.73M |
Revenue, most recent five fiscal years
| Fiscal year | Propanc Biopharma, Inc. | Nomad Power Solutions, Inc. | PMGC Holdings Inc. | NRX Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | n/a | $200.0K Ended 2015-12-31 | $590.1K Ended 2025-12-31 | $1.45M Ended 2025-12-31 |
| 1 year earlier | n/a | n/a | n/a | $0 Ended 2024-12-31 |
| 2 years earlier | n/a | $0 Ended 2013-12-31 | $1.71M Ended 2023-12-31 | $0 Ended 2023-12-31 |
| 3 years earlier | n/a | $0 Ended 2012-12-31 | $766.3K Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | $0 Ended 2011-12-31 | n/a | n/a |